The relationship between insulin resistance and recurrent pregnancy loss in assisted reproductive technology: A retrospective case-control study

This is the authors' abstract. We don't add key points for this paper.

This study aimed to investigate the association between insulin resistance (IR) and recurrent pregnancy loss (RPL) in patients undergoing assisted reproductive technology (ART). A retrospective analysis compared glucose and insulin indices (including fasting insulin [FINS], Homeostatic Model Assessment for Insulin Resistance [HOMA-IR], Homeostatic Model Assessment for Beta-Cell Function [HOMA-β], and area under the curve for insulin [AUCI] between RPL (n = 279) and non-RPL (n = 246) groups. Adjusted logistic regression models evaluated the correlation between IR-related indices and RPL risk. Compared with the non-RPL group, the RPL group exhibited significantly higher levels of FINS (10.67 vs. 8.57; P < .001), 1-hour insulin (1hINS) (110.86 vs. 74.75; P = .005), 2-hour insulin (2hINS) (89.47 vs. 67.94, P = .023), AUCI (117.08 vs. 114.16; P = .004), HOMA-IR (2.5 vs. 1.94; P < .001), HOMA-β (138.31 vs. 107.84; P < .001), the incidence of insulin resistance (63.47% vs. 47.03%; P < .001), and the incidence of HOMA-IR ≥ 2.14 (61.9% vs. 40.27%; P < .001). After adjusting for other factors, patients with IR had a higher risk of developing RPL compared with those without IR, with an odds ratio (OR) of 1.87 (95% CI: 1.18-2.94). Furthermore, an increase in FINS, HOMA-IR, and HOMA-β was associated with a significantly higher incidence of RPL, with OR values (95% CI) of 1.07 (1.03-1.12), 1.23 (1.03-1.48), and 1.01 (1.0-1.01), respectively. IR is an independent risk factor for RPL in ART patients, emphasizing the need for pretreatment interventions (e.g., lifestyle modifications or metformin) to improve insulin sensitivity and reduce miscarriage risk.